Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012

Looker, Katharine J; Magaret, Amalia; May, Margaret T; Turner, Katherine Mary Elizabeth; Vickerman, Peter; Gottlieb, Sami L.; Newman, Lori M.

doi:10.1371/journal.pone.0140765

Cited by 490 publications

(454 citation statements)

References 37 publications

(57 reference statements)

Supporting

Mentioning

429

Contrasting

Unclassified

Order By: Relevance

“…1,2 In 2012, HSV-1 prevalence was estimated at 3.7 billion people globally between the ages of 0 and 49 years, with an estimated 140 million people ages 15 to 49 years having genital HSV-1 infections. 3 The HSV-2 prevalence in 2012 was estimated at 417 million individuals worldwide between the ages of 15 and 49 years. 4 The burden increases risk of transmission of HSV infections to neonatal offspring.…”

Section: Introductionmentioning

confidence: 99%

Neonatal Herpes Simplex Viral Infections and Acyclovir: An Update

Harris¹,

Holmes²

2017

The Journal of Pediatric Pharmacology and Therapeutics

View full text Add to dashboard Cite

Neonatal herpes simplex virus (HSV) infections have high morbidity and mortality rates. Optimization of treatment and prevention strategies are imperative to improve the care and outcomes of neonates infected with HSV. Management of HSV includes reducing neonatal transmission, treating acute infections, and limiting adverse neurodevelopmental outcomes and future cutaneous outbreaks after acute infections. Transmission risk may be affected by route of delivery and maternal suppressive therapy. Neonatal HSV infections are divided into 3 categories: localized skin, eyes, or mouth; localized central nervous system; or disseminated infections. Parenteral acyclovir, the pharmacologic agent of choice, is used when treating each type of infection. However, dosage strategies and durations of therapy may vary based on disease state severity, presentation, and patient characteristics. Oral acyclovir may be used as suppressive therapy after acute treatment completion in specific neonatal populations, reducing long-term adverse neurodevelopmental outcomes and future skin eruptions. The mortality rate remains high even with treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Neonatal Herpes Simplex Viral Infections and Acyclovir: An Update

Harris¹,

Holmes²

2017

The Journal of Pediatric Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

“…The prevalence of HSV-1 and 2 differs widely between and within countries (Looker et al, 2015). Daily suppressive therapy with acyclovir, famciclovir and valacyclovir decreases HSV shedding dramatically and thereby decreases transmission along with decreased HIV viral loads (Nag et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Prevalence of HSV1 and HSV2 among HIV Patients in Northern South Africa as Determined by Real Time PCR in Urine Samples

Samie¹,

Mnisi²,

Ramantswana³

2017

American Journal of Infectious Diseases

View full text Add to dashboard Cite

The present study determined the prevalence of HSV-1 and 2 among HIV patients in Northern South Africa and identified potential risk factors. Urine samples were collected from patients attending different HIV clinics in Limpopo Province. Total genomic DNA was isolated from these samples using GenElute Blood Genomic DNA Kit and real time PCR protocols were used for the detection of HSV1 and HSV2. Demographic, clinical and socioeconomic data were collected using a structured questionnaire. The overall prevalence of HSV1 was 48.5% while that of HSV2 was 10.8% from a total of 308 samples. The prevalence of HSV1 was higher among females while that of HSV2 did not vary between males and females. Patients on zidovudine had a much lower prevalence. Patients who had TB (χ 2 = 9.128; p = 0.003), seemed to have a much higher susceptibility to HSV-1.However, this was not the case with HSV2. CD4 count and viral load did not seem to have any impact of the occurrence of HSV among these patients. Urine samples appear to be a useful alternative for the detection of the HSV. Generally, history of TB, usage of certain ARVs and early age of sexual debut appeared to be important risk factors for HSV.

show abstract

“…1 Among the two herpes simplex viruses, HSV-1 infection is more prevalent, affecting 3709 million people across the world (67%) belonging to the age group 15 -49 years. 2 Whereas, HSV-2 is less prevalent than HSV-1 and it affects 417 million people (11.3%) world over. 3 Herpes simplex is a recurrent self limiting viral infection.…”

Section: Introductionmentioning

confidence: 99%

Patient Reported Outcomes and Patient Satisfaction With Hyperisince® (An Ayurvedic Medicine/Poly-Herbal Combination) in Herpes Simplex

Kamat¹,

Sandhu²

2017

Int. J. Res. Ayurveda Pharm.

View full text Add to dashboard Cite

Herpes simplex is a highly prevalent, self limiting viral infection. Complications, drug resistance and side-effects of anti-viral drugs make treatment of herpes simplex challenging. Herbal/Ayurvedic medicines have shown potential in herpes simplex management. We conducted a survey to know the patient reported outcomes of patented Ayurvedic formulation Hyperisince ® . 122 herpes simplex infected patients who were treated with Hyperisince ® were mailed a questionnaire containing 20 questions. The questions collected demographic information, disease information and patient feedback on Hyperisince ® . A total of 101 responses were eligible for evaluation. HSV-1 was present in 31 patients, 48 had HSV-2 and 17 were infected with both the types. Eighty eight (87.13%) were previously treated with other drugs and acyclovir was the most common previous treatment. Symptom relief was reported by 76% of patients. Duration of herpes and nerve pain decreased considerably following Hyperisince ® treatment. There was decrease in frequency of symptoms. The efficacy of Hyperisince ® was more pronounced when it was used for >4 months. Twenty one patients rated Hyperisince ® 10 out of maximum rating of 10 and 58 participants rated it ≥5. Hyperisince ® was effective in relieving symptoms, nerve pain, and improving overall well being. Hyperisince ® also reduced the likelihood of having another herpes outbreak, especially when taken for 4 months or more. Most patients rated efficacy as ≥5 in the scale of 10. Efficacy of Hyperisince ® was more pronounced when used for >4 months. Further clinical trials can confirm our findings.

show abstract

Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012

Cited by 490 publications

References 37 publications

Neonatal Herpes Simplex Viral Infections and Acyclovir: An Update

Neonatal Herpes Simplex Viral Infections and Acyclovir: An Update

Prevalence of HSV1 and HSV2 among HIV Patients in Northern South Africa as Determined by Real Time PCR in Urine Samples

Patient Reported Outcomes and Patient Satisfaction With Hyperisince® (An Ayurvedic Medicine/Poly-Herbal Combination) in Herpes Simplex

Contact Info

Product

Resources

About